

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53



Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Loren D. Walensky, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, and Funda Meric-Bernstam

In the original version of this article (1), author Loren D. Walensky is mistakenly omitted from the author list. This error has been corrected in the latest online HTML and PDF versions of the article and the authors' contributions and disclosures have been updated as necessary. The authors regret this error.

Reference

1. Saleh MN, Patel MR, Bauer TM, Goel J, Falchook GS, Shapiro GI, et al. Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53. *Clin Cancer Res* 2021;27:5236–47.

Published online January 19, 2022.

Clin Cancer Res 2022;28:429

doi: 10.1158/1078-0432.CCR-21-4241

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

©2022 The Authors; Published by the American Association for Cancer Research